DNA: Newly public Ginkgo Bioworks to trade under Genentech's old ticker symbol - Boston Business Journal
Short report on synthetic biology company Ginkgo Bioworks ($DNA), drops share price 20% so far : r/Biotechplays
IonQ Stock Falls After Short Report From Scorpion Capital
Cathie Wood's Ark snaps up over two million Ginkgo Bioworks shares (NYSE:DNA) | Seeking Alpha
Ginkgo Bioworks Hit After Short Seller Claims Business Model a 'Shell Game' | BioSpace
Ginko Bioworks: Short Attacke auf die Biotech-Schmiede – Ist Cathie Wood einem Schwindel aufgesessen? – Noch hält die Starinvestorin dagegen! | news | onvista
Ginkgo Bioworks Holdings (NYSE:DNA) - Stock Price, News & Analysis - Simply Wall St
![Post 185/Yr 6) ARK Investment Management Daily Trades 5/20/2022[Buying Gingko Bioworks!?Evidence of past short report? ]](https://thefinance.sg/wp-content/uploads/2022/05/aapl20moving20average205020and2020020ma-1.png "Post 185/Yr 6) ARK Investment Management Daily Trades 5/20/2022[Buying Gingko Bioworks!?Evidence of past short report? ]")
Post 185/Yr 6) ARK Investment Management Daily Trades 5/20/2022[Buying Gingko Bioworks!?Evidence of past short report? ]
Ginkgo Bioworks Responds to Short Seller Report - Nanalyze
Ginkgo Bioworks Soars After Attracting Another Big Investor - BNN Bloomberg
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
Ginkgo Bioworks Stock Sinks on Short Seller Report | Barron's
Ginkgo Bioworks Stock Price Sinks After Short-Seller Calls It a 'Frankenstein' Fraud
Analyzing Ginkgo Bioworks Holdings's Short Interest - Ginkgo Bioworks Holdings (NYSE:DNA) | Flipboard
Synthetic-Biology Startup Ginkgo Bioworks Closes $100M Series C - WSJ
Ginkgo Bioworks: Audacious vision — but unproven track record playing in major league
Ginkgo Bioworks Stock Price Sinks After Short-Seller Calls It a 'Frankenstein' Fraud
Scorpion Capital on Twitter: "1 We are short $DNA. Ginkgo Bioworks is a colossal scam, a Frankenstein mash-up of the worst frauds of the last 20 years. At $23B market cap, it
Ginkgo Bioworks says third quarter revenue was up, acknowledges investment firm report triggered a federal inquiry - The Boston Globe
Wall Street Darling Ginkgo (DNA) Caught in SPAC, Short-Seller Selloff - Bloomberg
Never Mind Ginkgo Bioworks' Drama -- This Synthetic Biology Stock Is Still a Buy | The Motley Fool
Ginkgo Bioworks 'a hoax for the ages,' says activist short seller firm | Fierce Biotech
Ginkgo Bioworks shares fall on Scorpion Capital short report | Seeking Alpha
Cathie Wood's ARK buys Ginkgo Bioworks on short report tumble | Seeking Alpha
